Search alternatives:
significant improvements » significant improvement (Expand Search)
improvements decrease » improvements increased (Expand Search), improvements across (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
Showing 261 - 280 results of 5,501 for search '(( significant decrease decrease ) OR ( significant improvements decrease ))~', query time: 0.48s Refine Results
  1. 261
    Effects of Kylo-0603 on the expression of related genes of the MASH mouse models.

    Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 262
    Plasma cholesterol and LDL-C levels.

    Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 263
    <sup>13</sup>C NMR spectra for Kylo-0603.

    <sup>13</sup>C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 264
    General procedure for the synthesis of A and A-c1.

    General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 265
    Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603 (0.1–10 mg/kg/day, as indicated).

    Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 266
    DIO Mice Liver Staining.

    DIO Mice Liver Staining. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 267
    Trends of peroxisome-related gene expression in liver tissue.

    Trends of peroxisome-related gene expression in liver tissue. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 268
    NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day).

    NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 269
    The body weight and cholesterol levels of the mice were recorded before the administration of the drug.

    The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 270
    Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combined with digital image analysis technique.

    Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 271
    The structures of T3 and Kylo-0603.

    The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 272
    Synthesis process of Kylo-0603.

    Synthesis process of Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 273
    ESI-HRMS spectra for Kylo-0603.

    ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 274
    General procedure for the synthesis of Kylo-0603.

    General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 275
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 276
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  17. 277
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  18. 278
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  19. 279
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  20. 280
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:

Search Tools: